New triple therapy aims to control advanced breast cancer with fewer side effects

NCT ID NCT05455619

Recruiting now Disease control Sponsor: SynDevRx, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, evexomostat, added to two standard treatments for a common type of advanced breast cancer (HR+, HER2-). The goal is to see if the triple combination is safe and can reduce high blood sugar side effects often caused by the standard drugs. About 52 adults with specific genetic changes in their cancer will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer hyperglycemia hyperinsulinism Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+/HER2-NEGATIVE BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Doctors Hospital of Laredo
RECRUITING

Laredo, Texas, 78045, United States
Hoag Memorial Hospital Presbyterian
RECRUITING

Newport, California, 92663, United States
Hope and Healing Cancer Services
RECRUITING

Hinsdale, Illinois, 60521, United States
Loma Linda University Cancer Center
RECRUITING

Loma Linda, California, 92354, United States
Miami Cancer Institute at Baptist Health
RECRUITING

Miami, Florida, 33176, United States
Penn State Milton S Hershey Medical Center
RECRUITING

Hershey, Pennsylvania, 17033, United States
SHARP Healthcare
RECRUITING

San Diego, California, 92123, United States
Trinity Health
RECRUITING

Ypsilanti, Michigan, 48197, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.